Sinopharm Group Co. Ltd. specialises in the distribution of pharmaceutical products and medical devices to hospitals, clinics, pharmacies and third-party distributors. The group also operates pharmacy chains. Net sales break down by activity as follows: - distribution of pharmaceutical products (71%) ; - distribution of medical devices (21.7%); - operation of directly-owned and franchised pharmacy chains (5.9%); - other (1.4%).

Employees

113,635

Sector

Pharmaceuticals

Calendar

2025-03-20 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-04	20.95 $	+0.72%	4,797,195
24-12-03	20.80 $	+1.22%	10,561,290
24-12-02	20.55 $	+1.23%	7,006,052
24-11-29	20.30 $	+1.00%	10,658,800
24-11-28	20.10 $	-3.13%	8,596,643

Delayed Quote Hong Kong S.E., December 04, 2024 at 03:08 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart SINOPHARM-GROUP-CO-LTD

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

19.47CNY

Average target price

21.36CNY

Spread / Average Target

+9.70%

Consensus

Profit revisions

estimates-change-chart SINOPHARM-GROUP-CO-LTD

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SINOPHARM-GROUP-CO-LTD

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 03:08:13 2024-12-04 am EST			5-day change	1st Jan Change
20.95 ^HKD	+0.72%		+2.44%	+2.44%

Oct. 28	Sinopharm Group Records Lower Attributable Profit for Nine Months to September	MT
Oct. 28	Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI

Capitalization	60.76B 64.91B 8.34B 7.93B 7.39B 6.59B 11.73B 706B 12.88B 91.88B 34.07B 290B 31.33B 30.63B 1,247B	P/E ratio 2024 *	7.45x	P/E ratio 2025 *	6.57x
Enterprise value	53.25B 56.89B 7.31B 6.95B 6.48B 5.77B 10.28B 619B 11.29B 80.53B 29.86B 254B 27.47B 26.85B 1,093B	EV / Sales 2024 *	0.09x	EV / Sales 2025 *	0.05x
Free-Float	42.99%	Yield 2024 *	4.12%	Yield 2025 *	4.5%

Sinopharm Group Records Lower Attributable Profit for Nine Months to September	Oct. 28	MT
Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	Oct. 27	CI
Sinopharm Group's Subsidiary Records 10% Lower Attributable Net Profit in Q3	Oct. 23	MT
Nomura Adjusts Sinopharm Group's Price Target to HK$28.46 From HK$30.33, Keeps at Buy	Oct. 18	MT
Sinopharm Group's H1 Profit Declines 10% as Revenue Drops	Sep. 24	MT
Shyndec Pharmaceutical's Chairman, President Resign	Aug. 28	MT
Sinopharm Group Co. Ltd. Announces Change in President	Aug. 27	CI
Sinopharm Group Co. Ltd. Announces Board and Committee Resignations	Aug. 27	CI
Sinopharm Group Co. Ltd. Announces Management Changes	Aug. 27	CI
Gland Pharma Limited Announces Cessation of Mr. Qiyu Chen as Director, Effective from August 30, 2024	Aug. 26	CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 21	CI
China National Accord Medicines' H1 Profit Slips 11%, Revenue Down 2%; Shares Drop 4%	Aug. 19	MT
Global markets live: Apple, Walt Disney, BHP, Intel, Take-Two...	Aug. 09

Nomura Adjusts Sinopharm Group's Price Target to HK$28.46 From HK$30.33, Keeps at Buy	Oct. 18	MT
Nomura Adjusts Sinopharm's Price Target to HK$30.33 From HK$32.39, Keeps at Buy	Jul. 25	MT
Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy	Mar. 11	MT
Nomura Adjusts Sinopharm Group's Price Target to HK$33.31 From HK$36.28, Keeps at Buy	23-10-19	MT
Nomura Adjusts Sinopharm's Price Target to HK$36.28 From HK$36.88, Keeps at Buy	23-07-27	MT

Sinopharm Group Co. Ltd. Stock

Equities

1099

CNE100000FN7

Pharmaceuticals

Valuation: Sinopharm Group Co. Ltd.

Chart: Sinopharm Group Co. Ltd.

Latest news: Sinopharm Group Co. Ltd.

Analysts' recommendations: Sinopharm Group Co. Ltd.

Press Releases: Sinopharm Group Co. Ltd.

News in other languages: Sinopharm Group Co. Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sinopharm Group Co. Ltd.

ETFs: Sinopharm Group Co. Ltd.

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sinopharm : 2024 Interim Report	Sep. 24	PU
Sinopharm : 2024 Interim Results Presentation	Aug. 25	PU
Sinopharm : 2023 Interim Results Presentation	23-08-27	PU
Sinopharm : 2022 Annual Results Presentation	23-03-27	PU
Sinopharm : 2022 Interim Report	22-09-21	PU

En Direct des Marchés : Stellantis, Eutelsat, Compagnie des Alpes, Generali, Expedia, Hargreaves Lansdown...	Aug. 09
Les investisseurs retrouvent leur sang-froid	Aug. 09
Borsa di Italia: Gli investitori si calmano	Aug. 09
Bolsa de Madrid: Los inversores recuperan la calma	Aug. 09
Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi	Apr. 22

1 day	+0.72%
1 week	+0.96%
Current month	+3.20%
1 month	+6.78%
3 months	+22.80%
6 months	-2.10%
Current year	+2.44%

Director	Title	Age	Since
Wan Yong Lian PSD	President	54	2024-08-26
Yi Jian Wu SEC	Corporate Secretary	54	-
Xiu Chang Jiang DFI	Director of Finance/CFO	60	2010-04-30

Manager	Title	Age	Since
Qi Yu Chen BRD	Director/Board Member	52	2010-04-30
Zheng Dong Liu BRD	Director/Board Member	54	2014-09-20
De Yong Wen BRD	Director/Board Member	52	2017-08-31

Name	Weight	AuM	1st Jan change	Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD	2.58%	4 M€	-27.92%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	1.36%	1 M€	-20.08%	-
KRANESHARES MSCI CHINA ESG LEADERS ETF - USD	0.48%	4 M€	-11.56%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD	0.47%	2 M€	-14.14%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SINOPHARM GROUP CO. LTD.	+0.72%	+0.96%	+10.50%	+23.96%	8.34B
MCKESSON CORPORATION	-0.54%	-1.13%	+32.99%	+182.61%	78.44B
CARDINAL HEALTH, INC.	+0.65%	+0.68%	+15.03%	+162.17%	29.83B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+0.33%	-2.95%	+19.12%	+15.20%	9.73B
HUADONG MEDICINE CO., LTD	-2.09%	+8.69%	-7.77%	+8.91%	9.13B
H. LUNDBECK A/S	-0.50%	-0.68%	+33.84%	-	5.94B
EBOS GROUP LIMITED	-1.30%	-0.26%	+1.26%	+5.02%	4.39B
GALENICA AG	-0.72%	-1.36%	+6.36%	+21.47%	4.31B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-0.55%	+4.63%	-6.53%	+4.78%	3.65B
CHINA NATIONAL MEDICINES CORPORATION LTD.	-0.06%	-1.74%	+11.09%	+11.13%	3.52B
Average	-0.31%	+0.34%	+11.59%	+48.36%	15.73B
Weighted average by Cap.	+0.15%	-0.24%	+22.18%	+130.57%

	2024 *	2025 *
Net sales	599B 640B 82.23B 78.23B 72.87B 64.95B 116B 6,966B 127B 906B 336B 2,857B 309B 302B 12,295B	651B 695B 89.29B 84.95B 79.13B 70.53B 126B 7,564B 138B 984B 365B 3,102B 336B 328B 13,351B
Net income	8.17B 8.73B 1.12B 1.07B 994M 886M 1.58B 95.04B 1.73B 12.36B 4.58B 38.97B 4.22B 4.12B 168B	9.22B 9.85B 1.27B 1.2B 1.12B 1B 1.78B 107B 1.96B 13.95B 5.17B 43.98B 4.76B 4.65B 189B
Net Debt	-7.5B -8.02B -1.03B -980M -913M -813M -1.45B -87.24B -1.59B -11.35B -4.21B -35.78B -3.87B -3.78B -154B	-28.36B -30.3B -3.89B -3.7B -3.45B -3.07B -5.48B -330B -6.01B -42.88B -15.9B -135B -14.63B -14.3B -582B